Cryoport, Inc. (NASDAQ:CYRX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Cryoport, Inc. (NASDAQ:CYRX) have been given a consensus recommendation of “Moderate Buy” by the six analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $11.83.

CYRX has been the subject of a number of research analyst reports. Roth Mkm reaffirmed a “buy” rating and set a $15.00 price target on shares of Cryoport in a research report on Tuesday, April 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of Cryoport in a research report on Monday, March 31st. Guggenheim began coverage on shares of Cryoport in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price target on the stock. Finally, UBS Group lifted their price objective on shares of Cryoport from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, April 1st.

Insider Activity at Cryoport

In other news, CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $6.29, for a total value of $29,059.80. Following the completion of the transaction, the chief executive officer now owns 765,399 shares in the company, valued at $4,814,359.71. This trade represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have sold 19,830 shares of company stock worth $118,353. Company insiders own 10.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. raised its holdings in Cryoport by 148.7% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock valued at $28,000 after acquiring an additional 2,120 shares during the period. Lazard Asset Management LLC bought a new stake in shares of Cryoport during the 4th quarter valued at $51,000. Avanza Fonder AB purchased a new stake in Cryoport during the 4th quarter worth about $64,000. Quarry LP bought a new position in Cryoport in the 4th quarter worth about $69,000. Finally, ProShare Advisors LLC purchased a new position in Cryoport during the 4th quarter valued at about $95,000. 92.90% of the stock is owned by institutional investors.

Cryoport Price Performance

CYRX opened at $5.34 on Monday. Cryoport has a 1 year low of $4.58 and a 1 year high of $19.00. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. The company has a market capitalization of $266.52 million, a price-to-earnings ratio of -1.58 and a beta of 1.67. The firm’s fifty day moving average price is $6.45 and its two-hundred day moving average price is $7.23.

Cryoport (NASDAQ:CYRX) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The firm had revenue of $59.53 million for the quarter, compared to analysts’ expectations of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same quarter last year, the firm posted ($0.29) earnings per share. As a group, analysts anticipate that Cryoport will post -0.99 earnings per share for the current fiscal year.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.